SciELO - Scientific Electronic Library Online

 
vol.19 número2MECANISMO MOLECULAR DE LAS ESTATINAS EN EL TRATAMIENTO DE LA ERITROCITOSIS PATOLÓGICA DE ALTURA índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Médica La Paz

versión On-line ISSN 1726-8958

Resumen

RICARDO, Amaru et al. HIGH ALTITUDE PATHOLOGICAL ERYTHROCYTOSIS: BIOLOGICAL CHARACTERIZATION, DIAGNOSIS AND TREATMENT. Rev. Méd. La Paz [online]. 2013, vol.19, n.2, pp. 5-18. ISSN 1726-8958.

Introduction. The residents of high altitude get use to it in different ways, following the same purpose in order to supply oxygen and survival. In the present paper, we characterize the High Altitude Pathological Erythrocytosis disease and demonstrate the effectiveness of atorvastatin in its treatment. Material and methods. We studied male subjects as normal controls (CN), and patients with High Altitude Pathological Erythrocytosis (EPA), Secondary Erythrocytosis (ES) and Polycythemia Vera (PV). Laboratory and molecular biology studies were conducted. We developed in the study of 2nd phase with atorvastatin. Results. The EPA presents: normal erythropoietin, delayed erythroid progenitors apoptosis, autonomous growth of BFU-E and hypersensitivity to erythropoietin. The atorvastatin in patient with EPA, decreased hemoglobin concentration and eliminates the symptomatology of blood hyperviscosity Conclusions. The EPA has characteristics that distinguish it from other pathologic erythrocytosis and atorvastatin becomes an effective treatment.

Palabras clave : High Altitude Pathological Erythrocytosis; Chronic Mountain Sickness; Statins.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License